Evidence map›Paper›PMID 34765443›Full record

ReviewAsian journal of urology2021

Future perspective of focal therapy for localized prostate cancer.

Luke P O'Connor, Shayann Ramedani, Michael Daneshvar, Arvin K George, Andre Luis Abreu, Giovanni E Cacciamani, Amir H Lebastchi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luke P O'ConnorUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shayann RamedaniCollege of Medicine, The Pennsylvania State University, Hershey, PA, USA.
Michael DaneshvarUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Arvin K GeorgeDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Andre Luis AbreuCenter for Image-Guided and Focal Therapy for Prostate Cancer, Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Giovanni E CacciamaniCenter for Image-Guided and Focal Therapy for Prostate Cancer, Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Amir H LebastchiCenter for Image-Guided and Focal Therapy for Prostate Cancer, Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo summarize the recent literature discussing focal therapy for localized prostate cancer.

methodsA thorough literature review was performed using PubMed to identify recent studies involving focal therapy for the treatment of localized prostate cancer.

resultsIn an effort to decrease the morbidity associated with prostate cancer treatment, many urologists are turning to focal therapy as an alternative treatment option. With this approach, the cancer bearing portion of the prostate is targeted while leaving the benign tissue untouched. Multiparametric magnetic resonance imaging remains the gold standard for visualization during focal therapy, but new imaging modalities such as prostate specific membrane antigen/positron emission tomography and contrast enhanced ultrasound are being investigated. Furthermore, several biomarkers, such as prostate cancer antigen 3 and prostate health index, are used in conjunction with imaging to improve risk stratification prior to focal therapy. Lastly, there are several novel technologies such as nanoparticles and transurethral devices that are under investigation for use in focal therapy.

conclusionFocal therapy is proving to be a promising option for the treatment of localized prostate cancer. However, further study is needed to determine the true efficacy of these exciting new technologies.

Indexed as

Focal therapyImagingInnovationMultiparametric magnetic resonance imagingProstate cancerTechnology

Identifiers

PMID34765443
PMCPMC8566361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.